On January 14, 2025 LifeArc and Cleveland Clinic, a nonprofit, multispecialty academic medical centre, reported the companies have signed a new 10-year Master Services Agreement (MSA) for the development of novel monoclonal antibody-based therapeutics for patients with unmet medical needs (Press release, LifeArc, JAN 14, 2025, View Source [SID1234649709]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
LifeArc will provide its expertise in humanisation of monoclonal antibodies (mAbs) to target key drivers of conditions identified by Cleveland Clinic including cancer and complement-mediated diseases. This MSA builds on a successful track record of the two organisations working together since 2019 on four humanisation projects, with a fifth project for 2025 already underway.
Professor Feng Lin, Lerner Research Institute, Cleveland Clinic said: "Working with LifeArc is a collaboration. Both sides of the team come together and bring their respective expertise to take the project forward."
Dr. Jason Slingsby, Chief Business Officer at LifeArc said: "This collaboration with Cleveland Clinic is a groundbreaking moment for research into the development of monoclonal antibodies. Combining our expertise could lead to the development of new clinical candidate mAbs and give hope to patients who need it the most. Monoclonal antibodies are offering us new ways to target a wide range of conditions and I’m excited to see what our collaboration will develop over the next 10 years.
The agreement brings together two leading innovators in monoclonal antibody development to deliver new treatments for patients with unmet medical needs. Cleveland Clinic, based in Cleveland, Ohio, with locations around the world, is renowned for delivering high-quality research and cutting-edge treatments to patients. LifeArc brings over 30 years of expertise in antibody humanisation and engineering, which has seen five licensed medicines on the market including Keytruda (pembrolizumab), one of the best-selling cancer treatments in 2024, and Leqembi(lecanemab), a new treatment for early-stage Alzheimer’s disease.